Table 1.
Summary of patient characteristics.
| Characteristics | mean | (range) | |
|---|---|---|---|
| Age in years | |||
| Patients (N = 118) | 53 | (20-69) | |
| Sex | n | (%) | |
| male | 66 | 55.9 | |
| female | 52 | 44.1 | |
| Diagnosis | |||
| Acute leukemia | 67 | 56.8 | |
| Myelodysplastic syndrome | 14 | 11.9 | |
| Myeloproliferative syndrome | 7 | 5.9 | |
| Lymphoma | 30 | 25.4 | |
| Stage of underlying disease | |||
| Early | 34 | 28.8 | |
| Intermediate | 44 | 37.3 | |
| Advanced | 40 | 33.9 | |
| Donor type | |||
| Unrelated donor | 74 | 62.7 | |
| Sibling | 38 | 32.2 | |
| Haploidentical donor | 6 | 5.1 | |
| Stem cell source | |||
| PBSC | 110 | 93.2 | |
| BM | 8 | 6.8 | |
| Conditioning regimen | |||
| Reduced intensity | 104 | 88.1 | |
| Standard | 14 | 11.9 | |
| Immunosuppression | |||
| CyA/MTX | 96 | 81.4 | |
| CyA/MMF | 13 | 11.0 | |
| Tacro/MMF | 3 | 2.5 | |
| PostTxCy/Tacro/MMF | 6 | 5.1 | |
| Clinical GI-GvHD stage at time of biopsy | |||
| No GvHD | 60 | 50.8 | |
| Stage 1 | 32 | 27.1 | |
| Stage 2 | 11 | 9.3 | |
| Stage 3 | 8 | 6.8 | |
| Stage 4 | 7 | 5.9 | |
| Lerner GI-GvHD stage at time of biopsy | |||
| No GvHD | 56 | 47.4 | |
| Grade 1 | 36 | 30.5 | |
| Grade 2 | 11 | 9.3 | |
| Grade 3 | 9 | 7.6 | |
| Grade 4 | 6 | 5.1 | |
PBSC, peripheral blood stem cells; BM, bone marrow; CyA, cyclosporin; MTX, methotrexate; MMF, mycophenolate mofetil; Tacro, tacrolimus; PostTxCy, post-transplant cyclophosphamide.